Skip to main content
. 2021 Aug 31;97(9):e890–e901. doi: 10.1212/WNL.0000000000012449

Figure 2. MS Disease Outcomes: Relapse Rate, MRI New Lesions, and Change in EDSS Score.

Figure 2

(A) Annualized relapse rates (ARRs) over 2 years before autologous hematopoietic stem cell transplantation (AHSCT) and over up to 4 years after AHSCT demonstrate a significant reduction (mean ± 95% confidence interval, p < 0.001). (B) New MRI T2 lesion development over 1 year before and over up to 4 years was categorized, and the comparison demonstrated a significant reduction (χ2, p < 0.001). (C) Change in Expanded Disability Status Scale (EDSS) score before and after AHSCT over 12 months before transplantation/12 months after transplantation compared to treatment baseline (day 0 being transplantation day) examined in the total population. (D) Subgroup analysis of change in EDSS score shows a difference in the relapsing vs progressive multiple sclerosis (MS) subgroups (p < 0.05, Mann-Whitney test).